Fig. 1 · Structure

Documents & Downloads

Vanoxerine 2HCl (GBR-12909)

Cat. No. A10725 CAS 67469-78-7

dopamine re-uptake inhibitor

Vanoxerine (GBR-12909) is a piperazine derivative which is a potent and selective DRI.

In Stock

Publications for Vanoxerine 2HCl

1 publication citing this product

  1. Alexander D H Kingdon, .et al. , J Antibiot (Tokyo), 2025, Jan;78(1):54-63 PMID: 39402358

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GBR-12909 dihydrochloride functionally inhibited human DAT in two engineered cell models. The indirect TRACT impedance assay gave apparent pIC50 values of 6.2 ± 0.1 in U2OS-DAT and 6.6 ± 0.1 in inducible HEK293 JumpIn-DAT cells (mean ± SEM; n = 4 each). These assay-dependent values describe dopamine-response modulation rather than direct transporter binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

The cellular response depended on the assay context. At 10 µM, GBR12909 shifted dopamine potency significantly in U2OS-DAT cells; the corresponding shift in JumpIn-DAT cells did not reach significance (p = 0.057). Inhibitor-only, transporter-expression and receptor-antagonist controls supported interpretation of the impedance response. [1]

Vanoxerine dihydrochloride also altered human cardiac model electrophysiology. Microtissues showed delayed repolarization and EAD-like events during spontaneous activity; events were absent with 1.5 Hz pacing. A second cardiomyocyte MEA model showed repolarization delays and EAD-like events, although the 100 nM, 1 Hz repolarization comparison had p = 0.0502. Substantial platform drug loss and differing model conditions limit concentration comparisons. [2]

Functional DAT inhibition in U2OS-DAT cells

Cell-based study · U2OS cells transiently expressing human DAT; endogenous D1-receptor impedance readout [1]

GBR12909 enhanced dopamine-dependent impedance responses. Mock transfection and D1-receptor antagonist controls support the transport-dependent interpretation. This is an indirect functional assay, not a direct dopamine-flux or binding-affinity measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apparent inhibition of DAT via dopamine-dependent impedancepIC50 6.2 ± 0.1; reported IC50 0.6 µM; n = 4 biological experiments, each in duplicate; mean ± SEM[1]
Dopamine apparent potency with versus without 10 µM GBR12909pEC50 5.2 ± 0.2 (n = 4) versus 4.0 ± 0.2 (n = 6); mean ± SEM; p < 0.01[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 pM–10 µM for inhibitor curve; 10 µM for dopamine-response comparison
Exposure duration
60 min pretreatment; 120 min after dopamine addition
Method
xCELLigence; net area under the impedance curve; fixed pseudo-Hill slope of 1
Vehicle
0.1% DMSO in PBS; dopamine vehicle contained 1 mM ascorbic acid in PBS
Co-treatment
Dopamine 3.16 µM for inhibitor potency; dopamine concentration-response experiment also evaluated
Methods and source locations

Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: GBR12909

Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.

Methods Chemicals and reagents; Cell pretreatment/stimulation; Results Figures 1–2 and Table 1; SI Figures S1–S2

Apparent inhibition of DAT via dopamine-dependent impedance: Pretreatment with increasing GBR12909 followed by 3.16 µM dopamine; AUC over 120 min — Table 1, U2OS-DAT GBR12909 + 3.16 µM dopamine row; Figure 2c–d

Dopamine apparent potency with versus without 10 µM GBR12909: Dopamine concentration-response; fixed pseudo-Hill slope 1 — Table 1; Figure 2a–b; Results DAT inhibition restores apparent potency

Functional DAT inhibition in inducible JumpIn-DAT cells

Cell-based study · HEK293 JumpIn-DAT cells induced with 1 µg/mL doxycycline; alpha-2 adrenergic receptor-dependent impedance readout [1]

Concentration-dependent enhancement of dopamine response gave an apparent inhibitor potency. The dopamine-potency shift with fixed 10 µM GBR12909 did not reach statistical significance (p = 0.057). Doxycycline-negative cells and receptor antagonists were controls; GBR12909 alone did not substantially change pretreatment impedance.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apparent inhibition of DAT via dopamine-dependent impedancepIC50 6.6 ± 0.1; reported IC50 0.2 µM; n = 4 biological experiments, each in duplicate; mean ± SEM[1]
Dopamine apparent potency with versus without 10 µM GBR12909pEC50 4.6 ± 0.2 (n = 4) versus 4.3 ± 0.0 (n = 9); mean ± SEM; p = 0.057[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 pM–10 µM for inhibitor curve; 10 µM for dopamine-response comparison
Exposure duration
60 min pretreatment; 30 min after dopamine addition
Method
xCELLigence; net AUC; fixed pseudo-Hill slope 1
Vehicle
0.1% DMSO in PBS; dopamine vehicle contained 1 mM ascorbic acid in PBS
Co-treatment
Dopamine 10 µM for inhibitor potency; cocaine was a separate comparator, not a co-treatment
Methods and source locations

Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: GBR12909

Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.

Methods; Results Figures 4–5 and Table 1; SI Figures S1–S2

Apparent inhibition of DAT via dopamine-dependent impedance: Increasing inhibitor followed by 10 µM dopamine; AUC over 30 min — Table 1, JumpIn-DAT +dox GBR12909 + 10 µM dopamine row; Figure 5c–d

Dopamine apparent potency with versus without 10 µM GBR12909: Dopamine concentration-response comparison — Table 1; Figure 5a–b; Results Characterization of DAT inhibitors

Repolarization and pacing-dependent events in human cardiac microtissues

Cell-based study · WTC11-GCaMP6f hiPSC-derived complex cardiac microphysiological system [2]

Vanoxerine delayed repolarization and produced early-afterdepolarization-like events during spontaneous activity. Events were absent at 1.5 Hz pacing despite repolarization prolongation. Cell-free exposure analysis found 99% drug loss in the platform; nominal concentrations must not be equated to measured free tissue exposure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Spontaneous voltage-readout EAD-like event incidenceObserved EADs Vehicle 0/4; 1 nM 0/4; 10 nM 2/4; 30 nM 2/4; 100 nM 1/4[2]
EAD-like events with 1.5 Hz pacingQualitative outcome No EAD events detected in voltage, calcium or contractility readouts; n = 4[2]
Nonspecific vanoxerine loss in cell-free MPSPercent drug loss 99%[2]

Literature-Reported Treatment Conditions

Treatment concentration
1, 10, 30 and 100 nM nominal, escalating
Exposure duration
30 min incubation at each concentration before acquisition (Methods 2.4)
Method
Optical voltage, calcium and contractility readouts; spontaneous and paced conditions
Vehicle
0.1% DMSO in maturation medium
Co-treatment
None; sotalol and dofetilide were separate positive-control experiments
Reported limits
Discussion 4.3 describes acute exposures as approximately 35 min per concentration; Methods specifies 30 min incubation. Actual tissue drug exposure was not established by cell-free effluent loss.
Methods and source locations

Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: Vanoxerine

Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.

Methods 2.1–2.6, 2.8–2.9; Results 3.1–3.4; Tables 1–2; Figure 3; SI Tables S1 and S3

Spontaneous voltage-readout EAD-like event incidence: Voltage-sensitive optical readout; N = 4 as reported. Independent donor/batch count is not specified for this condition. — Table 1 Observed EADs (Voltage); SI Table S3 p. 9 including vehicle

EAD-like events with 1.5 Hz pacing: Pacing-rate comparison; no exact graph amplitudes extracted — Results 3.2; Figure 3 and caption

Nonspecific vanoxerine loss in cell-free MPS: LC-MS/MS; effluent compared with unperfused control solution — Methods 2.8; Results 3.4; Table 2

Electrophysiological effects in human iPSC-derived cardiomyocytes

Cell-based study · Commercial iCell Cardiomyocytes2 on multielectrode arrays; spontaneous, 1 Hz and 1.5 Hz conditions [2]

Vanoxerine delayed repolarization and produced EAD-like events in this second cardiac model. At 100 nM and 1 Hz the repolarization comparison had p = 0.0502, outside the study p < 0.05 threshold. The model differed from the microfluidic system in cell source, media, exposure and platform; direct quantitative comparison is not justified.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EAD-like events in hiPSC-CM MEA recordingsQualitative outcome Detected as early as 1 nM at 1.5 Hz and at 100 nM at all tested frequencies; Figure 5 reports n = 6–12 per condition[2]
Repolarization prolongation at 100 nM, 1 Hz versus vehiclep value p = 0.0502[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.3–100 nM nominal
Exposure duration
1 h after compound application
Method
MEA field potentials; double-delta FPD corrected by baseline and plate/timepoint vehicle controls
Vehicle
Final DMSO did not exceed 0.1%; serum-free FluoroBrite DMEM
Co-treatment
None
Reported limits
Model-specific free exposure was not measured; Figure 5 sample counts vary by condition. LEAP traces are qualitative, with n = 1–2 in Table S5.
Methods and source locations

Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: Vanoxerine

Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.

Methods 2.7 and 2.9; Results 3.5; Figure 5; SI Tables S4–S5

EAD-like events in hiPSC-CM MEA recordings: MEA field potential readout; event incidence is not an IC50 — Results 3.5; Figure 5A–B and caption

Repolarization prolongation at 100 nM, 1 Hz versus vehicle: Double-delta field potential duration; no exact graph amplitude extracted — Results 3.5 parenthetical comparison; Figure 5B

In Vivo Studies

In adult zebrafish, a single reported 15 mg/kg intraperitoneal dose of GBR-12909 dihydrochloride increased homebase occupancy and immobile episodes in a 30 min open-field test beginning 30 min after administration (n = 12 per group). Total distance travelled did not differ significantly from saline controls. This acute behavioural experiment does not establish a chronic disease model or therapeutic benefit. [3]

Acute open-field behaviour in adult zebrafish

Animal study · Adult zebrafish (Danio rerio), mixed-sex approximately 50:50; 4–6 months; n = 12 per group [3]

A single reported 15 mg/kg injection increased immobile episodes and homebase occupancy, while total distance travelled and several other locomotor/exploratory endpoints did not differ significantly from saline controls. These are acute task-specific behavioural observations; dopamine levels and DAT occupancy were not measured.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time spent in homebase versus salineStatistical comparison Increased; t(22) = 2.686, p = 0.0135; n = 12 per group[3]
Immobile episodes versus salineStatistical comparison Increased; t(22) = 2.120, p = 0.0455; n = 12 per group[3]
Total distance travelled versus salineStatistical comparison No significant difference; t(22) = 0.4732, p = 0.6407; n = 12 per group[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration
Treatment course
30 min before a 30 min open-field test
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GBR 12909
15 mg/kg (reported dose)
Saline-injected control; n = 12 per groupA single reported 15 mg/kg injection increased immobile episodes and homebase occupancy, while total distance travelled and several other locomotor/exploratory endpoints did not differ significantly from saline controls. These are acute task-specific behavioural observations; dopamine levels and DAT occupancy were not measured.[3]
GBR 12909
Model: Adult zebrafish (Danio rerio), mixed-sex approximately 50:50; 4–6 months; n = 12 per group
Reported limits: Only one dose and acute timepoint; no sex-stratified analysis, zebrafish pharmacokinetics or direct dopamine measurement reported for this experiment.
Methods and source locations

Compound reported in the paper: Vanoxerine dihydrochloride (GBR-12909); Compound label in the paper: GBR 12909

Evidence applies to the reported dihydrochloride reagent and model; no Adooq lot validation or salt conversion.

Methods 2.1–2.5; Results 3.1; Figure 2 and caption

Time spent in homebase versus saline: Unpaired Student t-test; data shown as mean ± SEM; no exact means inferred from plot — Results 3.1; Figure 2C

Immobile episodes versus saline: Unpaired Student t-test — Results 3.1; Figure 2A

Total distance travelled versus saline: Unpaired Student t-test — Results 3.1; Figure 2A

GBR 12909 · Methods 2.3–2.4.1; Results 3.1; Figure 2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 67469-78-7
Applications dopamine re-uptake inhibitor
Formula C28H32F2N2O.2HCl
Molecular Weight 523.5
Synonyms GBR-12909
SMILES
C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 15 mg/mL (28.65 mM)
Water 4 mg/mL (7.64 mM)
Ethanol 2 mg/mL (3.82 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Sijben HJ, van den Berg JJE, Broekhuis JD, et al. A study of the dopamine transporter using the TRACT assay, a novel in vitro tool for solute carrier drug discovery. Scientific reports (2021). PMID: 33446713 DOI: 10.1038/s41598-020-79218-w Source material
  2. [2] Garcia MI, Bhardwaj B, Dame K, et al. Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential. Journal of cardiovascular development and disease (2025). PMID: 40863351 DOI: 10.3390/jcdd12080285 Source material
  3. [3] Pretzel CW, Moraes HS, Müller ML, et al. GBR 12909, a Selective Dopamine Transporter Inhibitor, Differentially Modulates Affective, Exploratory and Cognitive Domains in Zebrafish. The European journal of neuroscience (2026). PMID: 42618519 DOI: 10.1111/ejn.70651 Source material

Publications

1 publication citing this product

  1. Alexander D H Kingdon, .et al. , J Antibiot (Tokyo), 2025, Jan;78(1):54-63 PMID: 39402358

Added to your cart

View Cart Checkout
Loading...